| Literature DB >> 22555659 |
Sid P Kerkar1, Nicholas P Restifo.
Abstract
In this issue of Blood, Pegram and colleagues describe the ability to improve adoptive T-cell therapies by engineering T cells to secrete the potent proinflammatory cytokine IL-12.1 These exciting findings significantly extend previous observations made in a murine melanoma model targeting naturally occurring tumor antigens.2,3Entities:
Year: 2012 PMID: 22555659 DOI: 10.1182/blood-2012-03-415018
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113